This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes methods and compositions for reducing blood lipids in mammals using specific plant extracts, Dichrostachys glomerata and Cissus quadrangularis. The application, filed on September 26, 2024, outlines potential health benefits including increased GLP-1 levels and reduced visceral fat, food intake, blood lipids, total cholesterol, and total glucose.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in therapeutic areas related to lipid management and may be of interest to pharmaceutical and biotechnology companies for research and development purposes. Compliance officers in these sectors should be aware of emerging intellectual property in this space.